Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study.
Mi ZhouEsther W ChanJo Jo HaiEmmanuel Chun Ka WongYuk Ming LauDuo HuangCheung Chi LamChor Cheung Frankie TamYiu Tung Anthony WongSee Yue Arthur YungKi Wan Kelvin ChanYingqing FengNing TanJi-Yan ChenChi Yui YungKwok Lun LeeChun Wai ChoiHo LamAndrew NgKatherine FanMan Hong JimKai Hang YiuBryan P YanChung Wah SiuPublished in: BMJ open (2020)
ClinicalTrials.gov Registry (NCT04045093); pre-results.
Keyphrases
- atrial fibrillation
- open label
- left atrial
- clinical trial
- catheter ablation
- oral anticoagulants
- left atrial appendage
- study protocol
- direct oral anticoagulants
- phase ii
- randomized controlled trial
- mitral valve
- heart failure
- multiple sclerosis
- mass spectrometry
- percutaneous coronary intervention
- left ventricular
- phase iii
- early onset
- high intensity
- coronary artery disease
- squamous cell carcinoma
- acute coronary syndrome
- venous thromboembolism
- radiation therapy
- brain injury
- blood brain barrier
- drug induced